JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
926
Deutsche Bank
DB
$65.7B
| $72.6M | 0.01% |
7,106,674
+3,305,176
| +87% | +$39.5M |
2022 Q1
4 quarters
|
|
927
eBay
EBAY
$47.3B
| $72.4M | 0.01% |
1,632,727
-199,168
| -11% | -$9.13M |
2013 Q2
39 quarters
|
|
928
PUT
Home Depot
HD
$282B
| $72.3M | 0.01% |
245,100
-231,000
| -49% | -$70.8M |
2017 Q2
23 quarters
|
|
|
JBTM
929
JBT Marel
JBTM
$5.63B
| $72.2M | 0.01% |
660,946
+38,744
| +6% | +$4.1M |
2013 Q2
39 quarters
|
|
930
Bloom Energy
BE
$85.2B
| $72.2M | 0.01% |
3,622,761
+186,013
| +5% | +$4.07M |
2018 Q3
18 quarters
|
|
931
BlackLine
BL
$1.59B
| $71.9M | 0.01% |
1,070,931
-81,959
| -7% | -$5.65M |
2016 Q4
25 quarters
|
|
932
BellRing Brands
BRBR
$864M
| $71.4M | 0.01% |
2,100,039
-3,070,031
| -59% | -$90.7M |
2019 Q4
13 quarters
|
|
933
Macerich
MAC
$6.54B
| $71.2M | 0.01% |
6,716,461
+203,180
| +3% | +$2.41M |
2013 Q2
39 quarters
|
|
934
American International
AIG
$39.2B
| $71.1M | 0.01% |
1,412,522
-1,016,139
| -42% | -$59.3M |
2013 Q2
39 quarters
|
|
935
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$23.6B
| $71.1M | 0.01% |
1,407,370
-1,147,689
| -45% | -$57.6M |
2013 Q2
39 quarters
|
|
936
10x Genomics
TXG
$12.2B
| $71M | 0.01% |
1,272,735
+10,835
| +0.9% | +$506K |
2019 Q3
14 quarters
|
|
937
United Rentals
URI
$67.3B
| $70.9M | 0.01% |
179,248
+24,252
| +16% | +$10.2M |
2013 Q2
39 quarters
|
|
938
Paychex
PAYX
$35.2B
| $70.9M | 0.01% |
618,787
+112,415
| +22% | +$12.8M |
2013 Q2
39 quarters
|
|
939
Relay Therapeutics
RLAY
$4.15B
| $70.8M | 0.01% |
4,300,826
-169,072
| -4% | -$3.03M |
2020 Q3
10 quarters
|
|
940
Revolution Medicines
RVMD
$44.3B
| $70.7M | 0.01% |
3,262,638
+666,584
| +26% | +$16.4M |
2020 Q1
12 quarters
|
|
941
Evergy
EVRG
$18.3B
| $70.1M | 0.01% |
1,147,640
-830,975
| -42% | -$50.5M |
2018 Q2
19 quarters
|
|
942
Seadrill
SDRL
$2.74B
| $69.8M | 0.01% |
1,738,498
+145,214
| +9% | +$5.69M |
2022 Q4
1 quarter
|
|
943
PUT
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$44.6B
| $69.8M | 0.01% |
209,900
-171,700
| -45% | -$57.1M |
2021 Q4
5 quarters
|
|
|
BPMC
944
DELISTED
Blueprint Medicines
BPMC
| $69.8M | 0.01% |
1,551,756
+103,541
| +7% | +$4.66M |
2015 Q2
31 quarters
|
|
945
iShares Russell Mid-Cap Value ETF
IWS
$14.9B
| $69.4M | 0.01% |
653,327
-15,332
| -2% | -$1.67M |
2013 Q2
39 quarters
|
|
946
Qiagen
QGEN
$9.24B
| $69.3M | 0.01% |
1,422,508
+225,583
| +19% | +$11.5M |
2017 Q1
24 quarters
|
|
947
Crocs
CROX
$5.66B
| $69.1M | 0.01% |
546,449
+240,565
| +79% | +$29.1M |
2013 Q2
39 quarters
|
|
948
Leslie's
LESL
$1.36M
| $68.7M | 0.01% |
311,835
+117,936
| +61% | +$30.6M |
2020 Q4
9 quarters
|
|
949
Telus
TU
$12.7B
| $68.6M | 0.01% |
3,453,784
-20,295
| -0.6% | -$413K |
2013 Q2
39 quarters
|
|
|
ENLC
950
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $68.5M | 0.01% |
6,317,977
+3,763,192
| +147% | +$44.6M |
2013 Q2
39 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.